RXFP3 and depressive disorder: Therefore, it will be important to test the antidepressant potential of acute and chronic delivery of RXFP3 agonists against behavioral measures such as anhedonia and aberrant reward-associated perception, and memory in additional validated rodent models of depression, such as the chronic unpredictable mild stress, chronic social defeat, and chronic methamphetamine withdrawal models (Nestler and Hyman, 2010; Russo and Nestler, 2013) and/or assess effects on brain activity patterns (McNaughton and Gray, 2000).